Michael R. Migden
Department of Dermatology, Division of Internal Medicine
About Dr. Migden
Michael R. Migden, MD is a distinguished US-based dermatologist and Professor, Departments of Dermatology, Division of Internal Medicine and Head and Neck Surgery, Division of Surgery at the University of Texas MD Anderson Cancer Center, Houston, TX, USA. At MD Anderson his is program director of the ACGME Fellowship:Micrographic Surgery and Dermatologic Oncology. He also serves as faculty for the Department of Ophthalmic Plastic & Reconstructive Surgery. He has served as a principal investigator for studies on the smoothened inhibitors sonidegib, vismodegib, and taladegib and on immune therapy trials in non-melanoma skin cancer. Dr Migden has published numerous primary and expert review articles on basal cell carcinoma.
Present Title & Affiliation
Primary Appointment
Professor, Department of Dermatology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Professor, Department of Head and Neck Surgery, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 1997 | University of Utah School of Medicine, Salt Lake City, UT, USA, MD, Medicine |
| 1992 | University of Utah, Salt Lake City, UT, USA, BS, Biology |
Postgraduate Training
| 2005-2006 | Clinical Fellowship, Dermatology, Procedural Dermatology Fellowship, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 2004-2005 | Clinical Fellowship, Advanced Dermatologic Surgery Education, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 2001-2004 | Research Fellowship, Dermatology, Digital Media Education Research, Mayo Clinic, Rochester, MN |
| 1998-2001 | Clinical Residency, Dermatology, Mayo Clinic, Rochester, MN |
| 1997-1998 | Clinical Residency, Internal Medicine, Mayo Clinic, Rochester, MN |
Board Certifications
| 2002 | American Board of Dermatology |
Experience & Service
Academic Appointments
Associate Professor, Department of Dermatology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2011 - 2018
Administrative Appointments/Responsibilities
Faculty for Ophthalmic Plastic & Reconstructive Surgery Fellowship, Department of Ophthalmology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2010 - Present
Faculty for Procedural Dermatology Fellowship, Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008 - 2016
Institutional Committee Activities
Committee Member, Sedation & Procedures Committee, 2010 - Present
Committee Member, Clinical & Research Informatics Committee, 2010 - 2011
Committee Member, Secure Messaging Workgroup Committee, 2007 - 2008
Selected Publications
Peer-Reviewed Articles
- Migden MR, Khushalani NI, Chang ALS, Lewis KD, Schmults CD, Hernandez-Aya L, Meier F, Schadendorf D, Guminski A, Hauschild A, Wong DJ, Daniels GA, Berking C, Jankovic V, Stankevich E, Booth J, Li S, Weinreich DM, Yancopoulos GD, Lowy I, Fury MG, Rischin D. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. Lancet Oncol 21(2):294-305, 2020. e-Pub 2020. PMID: 31952975.
- Chen L, Parsons AM, Aria AB, Ciurea AM, Patel AB, Chan C, Griffin JR, Nguyen TH, Migden MR. Surgical Site Identification with Personal Digital Device: A Prospective Pilot Study. J Am Acad Dermatol 79(3):520-524, 2018. e-Pub 2018. PMID: 29524583.
- Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, Chung CH, Hernandez-Aya L, Lim AM, Chang ALS, Rabinowits G, Thai AA, Dunn LA, Hughes BGM, Khushalani NI, Modi B, Schadendorf D, Gao B, Seebach F, Li S, Li J, Mathias M, Booth J, Mohan K, Stankevich E, Babiker HM, Brana I, Gil-Martin M, Homsi J, Johnson ML, Moreno V, Niu J, Owonikoko TK, Papadopoulos KP, Yancopoulos GD, Lowy I, Fury MG. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med 379(4):341-351, 2018. e-Pub 2018. PMID: 29863979.
- Sekulic A, Migden MR, Lewis K, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang AL, Dirix L, Hou J, Yue H, Hauschild A, ERIVANCE BCC investigators. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. J Am Acad Dermatol 72(6):1021-1026.e8, 2015. PMID: 25981002.
- Migden MR, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, Herd RM, Kudchadkar R, Trefzer U, Gogov S, Pallaud C, Yi T, Mone M, Kaatz M, Loquai C, Stratigos AJ, Schulze HJ, Plummer R, Chang AL, Cornélis F, Lear JT, Sellami D, Dummer R. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicenter, randomised, double-blind phase 2 trial. Lancet Oncol 16(6):716-28, 2015. e-Pub 2015. PMID: 25981810.
- Sharpe HJ, Pau G, Dijkgraaf GJ, Basset-Seguin N, Modrusan Z, Januario T, Tsui V, Durham AB, Dlugosz AA, Haverty PM, Bourgon R, Tang JY, Sarin KY, Dirix L, Fisher DC, Rudin CM, Sofen H, Migden MR, Yauch RL, de Sauvage FJ. Genomic analysis of Smoothened inhibitor resistance in basal cell carcinoma. Cancer Cell 27(3):327-41, 2015. PMID: 25759019.
- Anzalone CL, Cohen PR, Migden MR, Tannir NM. Mohs surgery in metastatic cancer: renal cell carcinoma solitary cutaneous metastasis and visceral tumor metastases to skin treated with microscopically controlled surgical excision. Int J Dermatol 52(7):856-61, 2013. e-Pub 2013. PMID: 23675612.
- Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang AL, Low JA, Mackey HM, Yauch RL, Graham RA, Reddy JC, Hauschild A. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 366(23):2171-9, 2012. PMID: 22670903.
- Migden M, Chavez-Frazier A, Nguyen T. The Use of High Definition Video Modules for Delivery of Informed Consent and Wound Care Education in the Mohs Surgery Unit. Semin Cutan Med Surg 27(1):89-93, 2008. PMID: 18486030.
- Migden MR, Dennis WH, Clinch TE. Confirmatory Testing for Hepatitis B Surface Antigen in Processing Donor Tissue for Penetrating Keratoplasty. American Journal of Ophthalmology 122:439-442, 1996.
- Migden MR, Elkins BS, Clinch TE. Phototherapeutic Keratectomy for Corneal Scars. Ophthalmic Surgery and Lasers 5:S503-S507, 1996.
- Migden MR, Kling S, Araneo BA, Perkins SL, Trautman MS. Interleukin -10 Expression in Murine Bone Marrow Macrophages. Clinical Research 41:1:19A, 1993.
Abstracts
- Sekulic A, Migden MR, Oro AE. Dirix L, Lewis K, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang ALS, Caro I, Mackey HM, Yauch RL, Reddy JC, Hauschild A. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (aBCC): 24-month update of the pivotal ERIVANCE BCC study. AAD-W (2014) American Academy of Dermatology - 72nd Annual Meeting, 2014.
- Sekulic A, Hauschild A, Migden MR, Oro A, LoRusso P, Rudin C, Lewis K, Dirix L, Solomon J, Hainsworth J, Yue H, Hou J, Hoff D. Survival of Patients With Metastatic Basal Cell Carcinoma and Distant Metastases: the Effect of Vismodegib, a Hedgehog Pathway Inhibitor. 8th World Congress of Melanoma; Hamburg, Germany, 2013.
- Sekulic A, Migden MR, Oro A, Dirix L, Lewis K, Hainsworth J, Solomon J, Hou J, Lyons B, Schadendorf D. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (aBCC): 24-month update of the pivotal ERIVANCE BCC study. American Academy of Dermatology (AAD) 2013, 2013.
- Sekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, Lao C, Miller C, Mortier L, Murrell D, Hamid O, Quevendo J, Hou J, Mackey H, Schadendorf D. Long-Term Safety and Efficacy of Vismodegib in Patients with Advanced Basal Cell Carcinoma (aBCC): 18-Month Update of the Pivotal ERIVANCE BCC Study. American Society of Clinical Oncology (ASCO) 2013, 2013.
- Sekulic A, Migden MR, Oro A, Dirix L, Lewis K, Hainsworth J, Solomon J, Hou J, Lyons B, Schadendorf D. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (aBCC): 24-month update of the pivotal ERIVANCE BCC study. European Academy of Dermatology and Venereology (EADV) 2013, 2013.
- Sekulic A, Migden MR, Oro A, Lewis K, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang ALS, Dirix L, Hou J, Yue H, Hauschild A. Efficacy and safety of vismodegib in patients with advanced basal cell carcinoma (BCC): 12-month update of the Erivance BCC study. SMR 2012 (2012) Society for Melanoma Research 2012 Congress, 2012.
- Sekulic A, Migden M, Oro A, Dirix L, Lewis K, Hainsworth J, Yoo S, Arron S, Friedlander P, Marmur E, Rudin C, Change A, Low J, Mueller AB, Yauch R, Reddy J, Hauschild A. A pivotal study evaluating efficacy and safety of the hedgehog pathway inhibitor (HPI) vismodegib (GDC-0449) in patients with locally advanced (la) or metastatic (m) basal cell carcinoma (BCC). 7th European Association of Dermato-Oncology, Nantes, France, 2011.
Book Chapters
- Migden M, Silapunt S. Mohs Micrographic Surgery of the Periorbital Area. In: Smith's Ophthalmic Plastic & Reconstructive Surgery, 3rd edition. Springer Science+Business Media, 2011.
Books (edited and written)
- Rohrer TE, Cook JL, Nguyen TH, and Mellette RJ. Flaps and Grafts in Dermatologic Surgery DVD's. In: Flaps and Grafts in Dermatologic Surgery. Ed(s) Migden M. Elsevier, 2007.
- Alam M, Nguyen TH. Treatment of Leg Veins DVD. In: Treatment of Leg Veins. Ed(s) Migden M. Elsevier, 2006.
Patient Reviews
CV information above last modified August 30, 2024